Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.67 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067332 | 0.83 | TNF (0.50) | TNFPKMPOLBKDM4EMEN1 | |
| SCHEMBL2065995 | 0.80 | TNF (0.61) | TNFKDM4ECA1CA2 | |
| SCHEMBL2066640 | 0.80 | TNF (0.61) | TNFTGFBR1CA12CA1CA2 | |
| SCHEMBL2067972 | 0.80 | TNF (0.61) | TNFTGFBR1KCNH2 | |
| SCHEMBL2064906 | 0.77 | TNF (0.58) | TNFTGFBR1CA2 | |
| SCHEMBL2066936 | 0.76 | TNF (0.57) | TNFTGFBR1POLBKDM4E | |
| SCHEMBL2066977 | 0.75 | TNF (0.56) | TNFTGFBR1CA12CA1CA2 | |
| SCHEMBL7889526 | 0.72 | KDM4E (0.47) | TNFTGFBR1PKMPOLBKDM4E | |
| SCHEMBL2064992 | 0.71 | TNF (0.55) | TNFTGFBR1PRMT5WDR77CA12 | |
| SCHEMBL13304403 | 0.71 | KDM4E (0.40) | TNFPKMPOLBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148524-B2 | Process for producing sulfonyl chloride compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-1932846-B1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1932846-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SALL4, CLCN2, CLIC1 | TNF 4785/4885TGFBR1 2307/4885PKM 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.